Isofol Medical Logo

Isofol Medical

Developing a drug to enhance chemotherapy efficacy for solid tumors like colorectal cancer.

ISOFOL | ST

Overview

Corporate Details

ISIN(s):
SE0009581051
LEI:
549300MCXYAHG7VBHX75
Country:
Sweden
Address:
C/O Biotech Center, Arvid Wallgrens, 413 46 Göteborg
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company develops its primary drug candidate, arfolitixorin, with the aim of increasing the efficacy of first-line standard chemotherapy treatments for various solid tumors. A key area of development is colorectal cancer, where the company is conducting a Phase Ib/II clinical study to optimize the drug candidate's dosing regimen and therapeutic effect.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 08:00
Quarterly Report
Swedish 11.9 MB
2025-11-12 08:00
Quarterly Report
English 12.0 MB
2025-11-04 09:45
Board/Management Information
Isofol appoints nomination committee ahead of the Annual General Meeting 2026
English 454.1 KB
2025-11-04 09:45
Board/Management Information
Isofol har utsett valberedning inför årsstämman 2026
Swedish 377.2 KB
2025-09-23 10:45
Major Shareholding Notification
Swedish 10.5 KB
2025-08-26 08:00
Interim Report
Swedish 7.2 MB
2025-08-26 08:00
Interim Report
English 2.6 MB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Nytt antal aktier och röster i Isofol
Swedish 60.6 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Isofol
English 61.3 KB
2025-07-04 18:00
Share Issue/Capital Change
Isofol's rights issue fully subscribed – exercises overallotment for Japanese p…
English 128.5 KB
2025-07-04 18:00
Share Issue/Capital Change
Isofols företrädesemission övertecknad – utnyttjar övertilldelning till japansk…
Swedish 127.3 KB
2025-06-17 08:40
Prospectus
Isofol offentliggör prospekt i samband med bolagets företrädesemission
Swedish 98.7 KB
2025-06-17 08:40
Prospectus
Isofol publishes prospectus in connection with the company’s rights issue
English 119.6 KB
2025-06-11 14:00
Post-Annual General Meeting Information
Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on…
English 94.5 KB
2025-06-11 14:00
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma i Isofol Medical AB (publ) den 11 juni 2025
Swedish 74.5 KB

Automate Your Workflow. Get a real-time feed of all Isofol Medical filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Isofol Medical

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Isofol Medical via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-01-11 Magnus Hurst Other Buy 35,000 24,150.00 SEK
2022-09-12 AB Windar Other Buy 500,000 305,000.00 SEK
2021-12-09 Tony Gustavsson Other Sell 58,767 858.00 SEK
2021-12-09 Tony Gustavsson Other Sell 58,767 152.79 SEK
2021-06-14 HealthCom GmbH Other Buy 233,336 1,493,350.40 SEK
2021-06-10 Gustaf Albèrt Other Other 15,153 96,979.20 SEK
2020-11-23 Tony Gustavsson Other Buy 58,767 43,487.58 SEK
2020-11-23 Tony Gustavsson Other Buy 58,767 29,971.17 SEK
2020-11-16 Sven Eriksson Other Sell 58,767 43,487.58 SEK
2020-11-16 Sven Eriksson Other Sell 58,767 29,971.17 SEK

Peer Companies

STRANGER HOLDINGS PLC Logo
Mining and developing uranium and strategic metals with near-term production projects in Africa.
United Kingdom
STHP
Ströer SE & Co. KGaA Logo
A media company providing integrated out-of-home (OOH) and digital advertising solutions.
Germany
SAX
STUDIO ALICE Co.,Ltd. Logo
Specialized photo studios capturing family milestones with costumes, styling, and kimono rentals.
Japan
2305
Surrozen, Inc./DE Logo
Develops regenerative antibodies modulating the Wnt pathway to repair tissues and restore organs.
United States of America
SRZN
Develops digital therapeutics (DTx) and AI systems to streamline clinical development.
Japan
4263
SYNAIRGEN PLC Logo
Developing inhaled interferon beta treatments for severe viral lung infections in hospitalized patients.
United Kingdom
SNG
Synerga Fund Spolka Akcyjna Logo
Commercializes medical therapies globally using industrial property and copyrights for clinical use.
Poland
SNG
Synergie SE Logo
Offers global HR services, including temporary/permanent recruitment and workforce solutions.
France
SDG
SyntekaBio,Inc. Logo
AI drug discovery platform accelerating R&D with supercomputing, SaaS, and pre-made candidates.
South Korea
226330
Targetspot S.A. Logo
AdTech firm for digital audio monetization, connecting brands to publishers' audiences.
Belgium
ALTGS

Talk to a Data Expert

Have a question? We'll get back to you promptly.